Listed

Marker Therapeutics, Inc.

MRKRNasdaqCIK 1094038HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$751.7k, Q1 FY2026
Operating income−$2.6m, Q2 FY2026
Net income−$1.8m, Q2 FY2026
Marker Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k258Revenue, Q3 FY2023, three months to 2023-09-30$257.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure1,057Revenue, Q4 FY2023, three months to 2023-12-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000549. Derived: 12-month figure less the 9-month figure.Report this figure1,244Revenue, Q1 FY2024, three months to 2024-03-31$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure1,169Revenue, Q2 FY2024, three months to 2024-06-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure1,926Revenue, Q3 FY2024, three months to 2024-09-30$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure2,252Revenue, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure349Revenue, Q1 FY2025, three months to 2025-03-31$349.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure861Revenue, Q2 FY2025, three months to 2025-06-30$861.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure1,233Revenue, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure1,103Revenue, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure752Revenue, Q1 FY2026, three months to 2026-03-31$751.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figurenot reported
Research and development$k2,045Research and development, Q3 FY2023, three months to 2023-09-30$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure2,617Research and development, Q4 FY2023, three months to 2023-12-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001410578-25-000549. Derived: 12-month figure less the 9-month figure.Report this figure2,575Research and development, Q1 FY2024, three months to 2024-03-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure2,335Research and development, Q2 FY2024, three months to 2024-06-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure3,471Research and development, Q3 FY2024, three months to 2024-09-30$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure5,086Research and development, Q4 FY2024, three months to 2024-12-31$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure3,135Research and development, Q1 FY2025, three months to 2025-03-31$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure4,177Research and development, Q2 FY2025, three months to 2025-06-30$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure2,346Research and development, Q3 FY2025, three months to 2025-09-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure2,141Research and development, Q4 FY2025, three months to 2025-12-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure2,843Research and development, Q1 FY2026, three months to 2026-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure1,476Research and development, Q2 FY2026, three months to 2026-06-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Operating income$k(3,200)Operating income, Q3 FY2023, three months to 2023-09-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure(2,938)Operating income, Q4 FY2023, three months to 2023-12-31−$2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000549. Derived: 12-month figure less the 9-month figure.Report this figure(2,549)Operating income, Q1 FY2024, three months to 2024-03-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure(2,308)Operating income, Q2 FY2024, three months to 2024-06-30−$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(2,400)Operating income, Q3 FY2024, three months to 2024-09-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(3,861)Operating income, Q4 FY2024, three months to 2024-12-31−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(4,958)Operating income, Q1 FY2025, three months to 2025-03-31−$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(5,122)Operating income, Q2 FY2025, three months to 2025-06-30−$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure(2,137)Operating income, Q3 FY2025, three months to 2025-09-30−$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(1,884)Operating income, Q4 FY2025, three months to 2025-12-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(4,073)Operating income, Q1 FY2026, three months to 2026-03-31−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(2,620)Operating income, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Net income$k(2,982)Net income, Q3 FY2023, three months to 2023-09-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure(2,803)Net income, Q4 FY2023, three months to 2023-12-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000549. Derived: 12-month figure less the 9-month figure.Report this figure(2,393)Net income, Q1 FY2024, three months to 2024-03-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure(2,193)Net income, Q2 FY2024, three months to 2024-06-30−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(2,308)Net income, Q3 FY2024, three months to 2024-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(3,838)Net income, Q4 FY2024, three months to 2024-12-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(4,446)Net income, Q1 FY2025, three months to 2025-03-31−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(4,016)Net income, Q2 FY2025, three months to 2025-06-30−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure(1,999)Net income, Q3 FY2025, three months to 2025-09-30−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(1,703)Net income, Q4 FY2025, three months to 2025-12-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(3,179)Net income, Q1 FY2026, three months to 2026-03-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(1,826)Net income, Q2 FY2026, three months to 2026-06-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Diluted EPS$ per share(0.34)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure(0.25)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(0.26)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported(0.40)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure(0.12)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported(0.16)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.09)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Basic EPS$ per share(0.34)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figurenot reported(0.27)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure(0.25)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(0.26)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported(0.40)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.29)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure(0.12)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported(0.16)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.09)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure

Balance sheet

Cash and equivalents$11.3m, Q2 FY2026
Shareholders' equity$12.2m, Q2 FY2026
Marker Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m17.5Cash and equivalents, Q3 FY2023, at 2023-09-30$17.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure15.1Cash and equivalents, FY2023, at 2023-12-31$15.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure11.3Cash and equivalents, Q1 FY2024, at 2024-03-31$11.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure7.8Cash and equivalents, Q2 FY2024, at 2024-06-30$7.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure9.0Cash and equivalents, Q3 FY2024, at 2024-09-30$9.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure19.2Cash and equivalents, FY2024, at 2024-12-31$19.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure13.7Cash and equivalents, Q1 FY2025, at 2025-03-31$13.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure10.5Cash and equivalents, Q2 FY2025, at 2025-06-30$10.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure17.6Cash and equivalents, Q3 FY2025, at 2025-09-30$17.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure16.1Cash and equivalents, FY2025, at 2025-12-31$16.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure14.9Cash and equivalents, Q1 FY2026, at 2026-03-31$14.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure11.3Cash and equivalents, Q2 FY2026, at 2026-06-30$11.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Current assets$m19.5Current assets, Q3 FY2023, at 2023-09-30$19.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure17.1Current assets, FY2023, at 2023-12-31$17.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure14.1Current assets, Q1 FY2024, at 2024-03-31$14.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure11.7Current assets, Q2 FY2024, at 2024-06-30$11.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure10.9Current assets, Q3 FY2024, at 2024-09-30$10.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure22.0Current assets, FY2024, at 2024-12-31$22.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure17.0Current assets, Q1 FY2025, at 2025-03-31$17.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure14.8Current assets, Q2 FY2025, at 2025-06-30$14.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure21.7Current assets, Q3 FY2025, at 2025-09-30$21.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure19.1Current assets, FY2025, at 2025-12-31$19.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure17.4Current assets, Q1 FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure14.6Current assets, Q2 FY2026, at 2026-06-30$14.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Total assets$m19.5Total assets, Q3 FY2023, at 2023-09-30$19.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure17.1Total assets, FY2023, at 2023-12-31$17.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure14.1Total assets, Q1 FY2024, at 2024-03-31$14.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure11.7Total assets, Q2 FY2024, at 2024-06-30$11.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure10.9Total assets, Q3 FY2024, at 2024-09-30$10.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure22.0Total assets, FY2024, at 2024-12-31$22.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure17.0Total assets, Q1 FY2025, at 2025-03-31$17.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure14.8Total assets, Q2 FY2025, at 2025-06-30$14.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure21.7Total assets, Q3 FY2025, at 2025-09-30$21.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure19.1Total assets, FY2025, at 2025-12-31$19.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure17.4Total assets, Q1 FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure14.6Total assets, Q2 FY2026, at 2026-06-30$14.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Current liabilities$m2.8Current liabilities, Q3 FY2023, at 2023-09-30$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure3.1Current liabilities, FY2023, at 2023-12-31$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure2.3Current liabilities, Q1 FY2024, at 2024-03-31$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure2.0Current liabilities, Q2 FY2024, at 2024-06-30$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure3.5Current liabilities, Q3 FY2024, at 2024-09-30$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure3.5Current liabilities, FY2024, at 2024-12-31$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure2.5Current liabilities, Q1 FY2025, at 2025-03-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure4.3Current liabilities, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure3.3Current liabilities, Q3 FY2025, at 2025-09-30$3.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure2.3Current liabilities, FY2025, at 2025-12-31$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure3.6Current liabilities, Q1 FY2026, at 2026-03-31$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure2.4Current liabilities, Q2 FY2026, at 2026-06-30$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Total liabilities$m2.8Total liabilities, Q3 FY2023, at 2023-09-30$2.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure3.1Total liabilities, FY2023, at 2023-12-31$3.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure2.3Total liabilities, Q1 FY2024, at 2024-03-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure2.0Total liabilities, Q2 FY2024, at 2024-06-30$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure3.5Total liabilities, Q3 FY2024, at 2024-09-30$3.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure3.5Total liabilities, FY2024, at 2024-12-31$3.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure2.5Total liabilities, Q1 FY2025, at 2025-03-31$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure4.3Total liabilities, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure3.3Total liabilities, Q3 FY2025, at 2025-09-30$3.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure2.3Total liabilities, FY2025, at 2025-12-31$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure3.6Total liabilities, Q1 FY2026, at 2026-03-31$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure2.4Total liabilities, Q2 FY2026, at 2026-06-30$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m16.7Shareholders' equity, Q3 FY2023, at 2023-09-30$16.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure14.1Shareholders' equity, FY2023, at 2023-12-31$14.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure11.8Shareholders' equity, Q1 FY2024, at 2024-03-31$11.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure9.7Shareholders' equity, Q2 FY2024, at 2024-06-30$9.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure7.4Shareholders' equity, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure18.6Shareholders' equity, FY2024, at 2024-12-31$18.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure14.5Shareholders' equity, Q1 FY2025, at 2025-03-31$14.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure10.5Shareholders' equity, Q2 FY2025, at 2025-06-30$10.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure18.4Shareholders' equity, Q3 FY2025, at 2025-09-30$18.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure16.8Shareholders' equity, FY2025, at 2025-12-31$16.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure13.8Shareholders' equity, Q1 FY2026, at 2026-03-31$13.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure12.2Shareholders' equity, Q2 FY2026, at 2026-06-30$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure

Cash flow

Operating cash flow−$3.7m, Q2 FY2026
Marker Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(1,127)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001410578-24-001978. Derived: 9-month figure less the 6-month figure.Report this figure(2,368)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001410578-25-000549. Derived: 12-month figure less the 9-month figure.Report this figure(3,837)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure(3,568)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001410578-25-001826. Derived: 6-month figure less the 3-month figure.Report this figure1,197Operating cash flow, Q3 FY2024, three months to 2024-09-30$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-111502. Derived: 9-month figure less the 6-month figure.Report this figure(4,703)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(5,500)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(1,878)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097262. Derived: 6-month figure less the 3-month figure.Report this figure(2,736)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-111502. Derived: 9-month figure less the 6-month figure.Report this figure(1,900)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(1,404)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(3,716)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097262. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Share repurchases$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)19.31m, Q2 FY2026
Marker Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares8.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-308,359,920 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001410578-23-002307.Report this figure8.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-318,721,031 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001410578-24-000865.Report this figure8.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-308,798,956 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001410578-24-001454.Report this figure8.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-308,825,881 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001410578-24-001978.Report this figure8.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-318,901,962 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001410578-25-001342.Report this figure8.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-308,918,233 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure8.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-308,923,170 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure11.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3111,106,027 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure14.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3013,956,562 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure16.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3016,757,678 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure19.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3119,314,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure19.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3019,314,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure

Shares outstanding: 16.67mShares outstanding, period not labelled, at 2026-08-0716,673,127 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.